|
Market Closed -
Nasdaq
23:00:00 26/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.580 USD | -7.97% |
|
+1.99% | -37.95% |
| 10-21 | Unicycive Therapeutics Shares Rise After FDA Accepts Resubmitted NDA | DJ |
| 10-21 | Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 99.72M | - | - | - | - | - |
| 65.28B | |||||
| 54.57B | |||||
| 53.59B | |||||
| 45.03B | |||||
| 42.17B |
Select your edition
All financial news and data tailored to specific country editions
